Dr. Reddy's Laboratories Limited has informed the Exchange about Action(s) taken or orders passed
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty 100 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories has received five separate orders from the Joint Commissioner of Central Tax, Visakhapatnam, alleging that the company availed excess input tax credit under the APGST Act 2017 for FY 2018-19 to FY 2022-23. Total penalty across the five financial years amounts to approximately ₹8.39 crore, with the largest being ₹3.53 crore for FY 2020-21 and the smallest ₹70.87 lakh for FY 2022-23. The company has stated that there is no material impact on its financials, operations, or other activities. Dr. Reddy's plans to evaluate filing appeals with the appellate authority against these orders.
The financial impact is described as immaterial by the company, and total penalties of ~₹8.39 crore are small relative to Dr. Reddy's scale, so this is unlikely to move the stock. However, investors should watch for the appeal outcome, as a sustained tax demand could affect future earnings if not overturned.